mRNA expression pattern of retinoic acid and retinoid X nuclear receptor subtypes in human thyroid papillary carcinoma

Macejová,Dana; Galbavý,Štefan; Podoba,Ján; Bialešová,Lucia; Brtko,Július

doi:10.3892/or.2013.2670

mRNA expression pattern of retinoic acid and retinoid X nuclear receptor subtypes in human thyroid papillary carcinoma

Authors:
- Dana Macejová
- Štefan Galbavý
- Ján Podoba
- Lucia Bialešová
- Július Brtko
View Affiliations

Affiliations: Institute of Experimental Endocrinology, Slovak Academy of Sciences, 833 06 Bratislava, Slovak Republic, Department of Pathology, St. Elizabeth University of Health and Social Sciences and St. Elisabeth Institute of Oncology, 812 50 Bratislava, Slovak Republic, Department of Endocrinology, St. Elisabeth Institute of Oncology, 812 50 Bratislava, Slovak Republic
Published online on: August 20, 2013 https://doi.org/10.3892/or.2013.2670
Pages: 2371-2378

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Retinoids have shown potential for the inhibition of tumour growth and progression. The objective of this study was to investigate retinoic acid nuclear receptor subtypes RAR/RXR and iodothyronine 5'-deiodinase, type I expression pattern in papillary thyroid tumour tissue of 26 patients in order to compare with those of the non-neoplastic thyroid tissue of the corresponding patients. The expression of selected parameters mRNA was examined by semi-quantitative RT-PCR. Papillary thyroid carcinoma (PTC) expressed RXRγ, when compared to non-neoplastic thyroid tissues of the corresponding patients that were lacking expression of RXRγ or its expression was very low. Moreover, we found significantly increased expression of RARα and RARγ in the overall group of PTC. This increase was detected in cases with positive lymph node metastasis (LNM), but not in cases with negative LNM. RARβ was significantly reduced in the subgroup of classic variant (CV). We also detected absence or significantly lower expression of hDIO1 mRNA in tumour tissue when compared to non-neoplastic tissue in both overall PTC cases and in the CV subgroup. However, the significantly decreased levels of hDIO1 mRNA were detected in cases with negative LNM but not in cases with positive LNM when compared to corresponding non-tumour tissue in both overall PTC cases and in the CV subgroup. Differences in RAR and RXR subtype mRNA expression patterns in various PTCs may contribute to the immunochemistry data available, and may thus find exploitation in clinical oncology, particularly in the differential diagnosis of thyroid neoplasms.

View Figures

View References

1	Lloyd RV, Buehler D and Khanafshar E: Papillary thyroid carcinoma variants. Head Neck Pathol. 5:51–56. 2011. View Article : Google Scholar
2	Slough CM and Randolph GW: Workup of well-differentiated thyroid carcinoma. Cancer Control. 13:99–105. 2006.PubMed/NCBI
3	LiVolsi VA: Papillary thyroid carcinoma: an update. Mod Pathol. 24(Suppl 2): S1–S9. 2011. View Article : Google Scholar
4	Bai Y, Kakudo K, Li Y, Liu Z, Ozaki T, Ito Y, Kihara M and Miyauchi A: Subclassification of non-solid-type papillary thyroid carcinoma identification of high-risk group in common type. Cancer Sci. 99:1908–1915. 2008.PubMed/NCBI
5	Bai Y, Kakudo K, Nakamura M, Ozaki T, Li Y, Liu Z, Mori I, Miyauchi A and Zhou G: Loss of cellular polarity/cohesiveness in the invasive front of papillary thyroid carcinoma and periostin expression. Cancer Lett. 281:188–195. 2009. View Article : Google Scholar : PubMed/NCBI
6	Liu Y, Lee MO, Wang HG, Li Y, Hashimoto Y, Klaus M, Reed JC and Zhang X: Retinoic acid receptor β mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol Cell Biol. 16:1138–1149. 1996.
7	DeGroot LJ, Kaplan EL, McCormick M and Straus FH: Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 71:414–424. 1990. View Article : Google Scholar : PubMed/NCBI
8	Hay ID: Papillary thyroid carcinoma. Endocrinol Metab Clin North Am. 19:545–576. 1990.
9	Brtko J: Retinoids, rexinoids and their cognate nuclear receptors: character and their role in chemoprevention of selected malignant diseases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 151:187–194. 2007. View Article : Google Scholar : PubMed/NCBI
10	Brtko J and Dvorak Z: Role of retinoids, rexinoids and thyroid hormone in the expression of cytochrome p450 enzymes. Curr Drug Metab. 12:71–88. 2011. View Article : Google Scholar : PubMed/NCBI
11	Brtko J and Thalhamer J: Renaissance of the biologically active vitamin A derivatives: established and novel directed therapies for cancer and chemoprevention. Curr Pharm Des. 9:2067–2077. 2003. View Article : Google Scholar : PubMed/NCBI
12	Schmutzler C, Brtko J, Bienert K and Köhrle J: Effects of retinoids and role of retinoic acid receptors in human thyroid carcinomas and cell lines derived therefrom. Exp Clin Endocrinol Diabetes. 104(Suppl 4): S16–S19. 1996. View Article : Google Scholar : PubMed/NCBI
13	Liu Z, Zhou G, Nakamura M, Bai Y, Li Y, Ozaki T, Mori I, Miyauchi A and Kakudo K: Retinoid X receptor γ up-regulation is correlated with dedifferentiation of tumor cells and lymph node metastasis in papillary thyroid carcinoma. Pathol Int. 61:109–115. 2011.
14	Tang W, Nakamura Y, Zuo H, Yasuoka H, Yang Q, Wang X, Nakamura M, Mori I, Miyauchi A and Kakudo K: Differentiation, proliferation and retinoid receptor status of papillary carcinoma of the thyroid. Pathol Int. 53:204–213. 2003. View Article : Google Scholar : PubMed/NCBI
15	Casula S and Bianco AC: Thyroid hormone deiodinases and cancer. Front Endocrinol (Lausanne). 3:742012.
16	Greene FL and Sobin LH: The TNM system: our language for cancer care. J Surg Oncol. 80:119–120. 2002. View Article : Google Scholar : PubMed/NCBI
17	Kimura Y, Suzuki T, Kaneko C, Darnel AD, Moriya T, Suzuki S, Handa M, Ebina M, Nukiwa T and Sasano H: Retinoid receptors in the developing human lung. Clin Sci (Lond). 103:613–621. 2002.PubMed/NCBI
18	Brtko J, Sejnová D, Ondková S and Macejová D: Malignant Triton tumour exhibits a complete expression pattern of nuclear retinoid and rexinoid receptor subtypes. Gen Physiol Biophys. 28:425–427. 2009. View Article : Google Scholar : PubMed/NCBI
19	Franceschi S, Boyle P, Maisonneuve P, La Vecchia C, Burt AD, Kerr DJ and MacFarlane GJ: The epidemiology of thyroid carcinoma. Crit Rev Oncog. 4:25–52. 1993.
20	Clark DP and Faquin WC: Thyroid Cytopathology. Springer Science and Business Media Inc.; New York, NY: 2011
21	Amico P, Lanzafame S, Li Destri G, Greco P, Caltabiano R, Vecchio GM and Magro G: Warthin tumor-like papillary thyroid carcinoma with a minor dedifferentiated component: report of a case with clinicopathologic considerations. Case Report Med. 2010:4952812010.
22	Paker I, Kokenek TD, Yilmazer D, Seker GE and Alper M: Oncocytic variant of papillary thyroid carcinoma with lymphocytic stroma (Warthin-like variant): report of a case with fine needle variant cytology and review of the literature. Cytopathology. 23:408–410. 2012. View Article : Google Scholar
23	Hoftijzer HC, Liu YY, Morreau H, van Wezel T, Pereira AM, Corssmit EP, Romijn JA and Smit JW: Retinoic acid receptor and retinoid X receptor subtype expression for the differential diagnosis of thyroid neoplasms. Eur J Endocrinol. 160:631–638. 2009. View Article : Google Scholar : PubMed/NCBI
24	Haugen BR, Larson LL, Pugazhenthi U, Hays WR, Klopper JP, Kramer CA and Sharma V: Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab. 89:272–280. 2004. View Article : Google Scholar : PubMed/NCBI
25	Brtko J, Macejova D and Galbavy S: Thyroid non-Hodgkin's lymphoma expression pattern of nuclear retinoid and rexinoid receptor subtypes. Gen Physiol Biophys. 29:411–413. 2010.
26	Papi A, Rocchi P, Ferreri AM and Orlandi M: RXRγ and PPARγ ligands in combination to inhibit proliferation and invasiveness in colon cancer cells. Cancer Lett. 297:65–74. 2010.
27	Yen WC, Prudente RY, Corpuz MR, Negro-Vilar A and Lamph WW: A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br J Cancer. 94:654–660. 2006.PubMed/NCBI
28	Macejova D, Radikova Z, Macho L, Liska J and Brtko J: MNU-induced carcinogenesis of rat mammary gland: effect of thyroid hormone on expression of retinoic acid receptors in tumours of mammary gland. Mol Cell Endocrinol. 244:47–56. 2005. View Article : Google Scholar : PubMed/NCBI
29	Romitti M, Wajner SM, Zennig N, Goemann IM, Bueno AL, Meyer EL and Maia AL: Increased type 3 deiodinase expression in papillary thyroid carcinoma. Thyroid. 22:897–904. 2012. View Article : Google Scholar : PubMed/NCBI
30	Weinert LS, Ceolin L, Romitti M, Camargo EG and Maia AL: Is there a role for inherited TRβ mutation in human carcinogenesis? Arq Bras Endocrinol Metabol. 56:67–71. 2012.PubMed/NCBI
31	Macejova D, Ondkova S and Brtko J: Vitamin D3 affects expression of thyroid hormone receptor alpha and deiodinase activity in liver of MNU-treated Sprague-Dawley rats. Gen Physiol Biophys. 28:363–370. 2009. View Article : Google Scholar : PubMed/NCBI